Skip to main content
Join our webinar series discussing the latest developments in drug discovery. Register now.
Enquire

Domainex recognised as leading drug discovery CRO

OBN Awards best drug discovery CRO nominee banner

Whilst 2020 was undoubtedly a challenge, it also proved to be an exciting year for Domainex. Not only did Dr Tom Mander take over as CEO on Dr Trevor Perrior’s retirement, we also welcomed back Dr Eddy Littler as non-executive Chairman and launched our new brand and website as well as progressing several new and existing research partnerships. Building on this growth, we are excited to announce that we have been awarded ‘Drug Discovery CRO of the Year – Europe’ at the Healthcare & Pharmaceutical Awards and nominated for ‘Best CRO’ at the OBN Awards, recognising our position as a leading drug discovery contract research organisation (CRO).

Drug Discovery CRO of the Year – Europe

Global Health & Pharma: Healthcare & Pharmaceutical Awards

Domainex is proud to announce it has been awarded ‘Drug Discovery CRO of the Year – Europe’ at the Healthcare & Pharmaceutical Awards, hosted by Global Health & Pharma (GHP). This award recognises Domainex’s contribution to the industry, reflecting our expertise in drug discovery, dedication to customer service and commitment to promoting excellence.

Best CRO

OBN Awards

We have also been shortlisted as a finalist for ‘Best CRO’ at the OBN Awards. The OBN Awards celebrate outstanding achievement throughout the life sciences industry, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life tangible results. This award recognises outstanding performance by a CRO and Domainex was independently nominated on the basis of our truly integrated approach, offering bespoke programmes based on our clients’ specific needs. Our partners value this tailored input and we believe this, alongside our strong reputation of technical excellence and innovation, differentiates us from other CROs.

Congratulations and good luck to all the OBN finalists. The awards have been necessarily postponed until June, but we are looking forward to them and keeping our fingers crossed!

We’re proud of the amazing work the Domainex Team achieved last year, even with the additional challenges of implementing shift patterns, seven-day operations and social distancing. These awards and nominations reflect their fantastic commitment to delivering successful drug discovery research projects for our partners and we look forward to building on this progress in 2021.

Start your next project with Domainex

Contact one of our experts today